Glenmark Pharma gets 5 observations from U.S. FDA for its Goa, India Facility

The U.S. FDA has issued Form 483 with five observations after an inspection at Glenmark Pharmaceuticals Limited's formulation manufacturing facility based out of Goa, India between May 12, 2022 and May 20, 2022.

The company is committed to undertake all necessary steps required to address their observations at the earliest. The Company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 407.40 as compared to the previous close of Rs. 392.50. The total number of shares traded during the day was 33932 in over 1279 trades.

The stock hit an intraday high of Rs. 408.80 and intraday low of 397.05. The net turnover during the day was Rs. 13688287.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 Form483 5Observations USFDA Inspection Goa FormulationManufacturingFacility